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Abstract 
Carotid artery stenting becomes first 
intention treatment in atheromatous carotis 
artery stenosis. In this article we present our 
first experience in carotid artery stentig on 
27 consecutive patients. Demographic, 
clinic and angiographic dates are 
retrospectively review and technical success 
rate and postprocedural complication are 
statistically compared with literature trial 
studies.  
    Keywords: carotid stenosis, stroke, 
stents 
Introduction 
Cerebrovascular events due to 
atherosclerotic carotid artery disease 
represent 20 percent of all strokes. 
Percutaneous transluminal carotid 
angioplasty with stent becomes today the 
most used therapy for atheromatous causes 
of stenotic and occlusive disease of the 
internal carotid artery. Previously study 
trials have shown that the endovascular 
stenting treatment of carotid artery stenosis 
is an optimal therapy for carotid artery 
stenosis more that 70% in asymptomatic 
patients or more that 50% in symptomatic 
patients.   
In this study we report the efficiency, 
clinical and imagistic results in the stenting 
treatment of 27 consecutive patients with 
internal carotid artery stenosis.  
Methods  
All 27 patients included in the study 
benefit of an endovascular carotid stenting 
for unilateral or bilateral carotid artery 
stenosis between May 2010 and October 
2011. The first evidence of carotid stenosis 
was identified on non invasive test 
(Doppler sonography, angio-CT and angio-
MRI) in 20 patients and on invasive 
catheter angiography (in time of coronary 
and peripheral angiography) in 7 cases. 
Careful neurological evaluation was 
performed in all patients before 
endovascular intervention, 24 hours after 
procedure and at the periodical control at 2 
and 6 months by the same neurosurgeon 
specialists. Preprocedural cerebral CT scans 
were performed for the patients with 
permanent or remitted neurological deficits 
after a previously stroke (between 6-12 
months). Postprocedural cerebral CT scan 
was only performed in the patients with 
neurological deficits installed after a stroke 
suffered at more than 2 weeks before the 
procedure. Control catheter angiography 
was performed earlier than one year for the 
3 patients who benefit from a bilateral 
carotid stenting in two steps and after one 









Stenting procedure  
Before the procedure all patients 
received 100 mg acetylsalicylic acid and 75 
mg clopidogrel for at least 3 days. 300 mg 
clopidogrel loading dose was administrated 
on the same day of the procedure for those 
patients with no antiplatelet medication. A 
dose of 5000 units of heparine was 
administrated during the procedure to 
maintain an optimal activated clotting time 
between 200 and 250. 75 mg clopidogrel 
and 100 mg acetylsalicylic acid were 
continued to be administrated for at least 6 
months. For bradycardia and hypotension 
reaction prevention, potentially associated 
with carotid dilatation, 1 mg of atropine was 
intravenously administrated.  
Arterial blood pressure, EKG and O2 
saturation were continuously monitored 
during the procedures.   
All procedures were performed under 
local anesthesia with 5% lidocaine 
infiltrated at the access site. A standard 
retrograde trans-femural access through an 
8F vascular sheath was used for all stenting 
procedures.  Selective common carotid 
artery angiographies were obtained with an 
8F Mach1, Boston guiding catheter. The 
guiding catheters were advanced into the 
common carotid artery on support of a 
hydrophilic guide wire (0.035in, “J” peak, 
150cm length). After that, an angiographic 
examination of the stenotic carotid lesion in 
an optimal projection (clearly exposure of 
the carotid bifurcation) was done. Keeping 
this angiographic image as reference image 
on the secondary screen, an embolic 
protection device was thereafter employed. 
Two different embolic protection device 
were used, the Boston Scientific filter wire 
“EZ” in 6 patient and Abbott Emboshield 
NAV6 Embolic Protection System in 14 
patients. In 8 cases a predilatation 
procedure of the severe stenotic lesion with 
a 2.5/20 mm balloon was necessary for a 
safety embolic protection device passes 
(Table 3). 
A self-expandable stent was placed over 
the atheromatouse lesion. A Boston 
Scientific stent “Wallstent” was used in 8 
cases and an Abbott Xact Carotid Stent 
System was used in 19 cases. 17 patients 
benefited by postdilatation for intra-stent 
blood flow optimization with a 5.5/30mm 
balloon. A final carotid angiographic 
exposure is performed (Figure 1).   
All the patients were discharged at home 
at two days except 4 patients who were 
transferred to neurology. 
 
 
Figure 1 Angiography images with A ICA stenosis  
B intrastent balloon postdilatation  
C ICA dilatated with stent 
 
TABLE 1 
Criteria for high-risk patients: 
Pathologic Criteria  Cases 
Age over 80 years - 
History of open heart surgery - 
Need for open heart surgery within 30 days 1 
Multi-vessel atherosclerosis 2 
Left ventricular dysfunction with ejection 
deficit fraction <40% 
- 
Old myocardial infarction with coronary stenting 3 
Severe bronchopulmonary disease - 
Severe renal diseas - 
Significant contralateral carotid artery disease 6 











Demographic, clinic and 
angiographic dates 
Criteria  No. 
Age (Mean + SD) years 61 + 12 
Gender (male / female) 18 / 9 
Symptomatic / Asymptomatic 15 / 13 
Hemiplegia / Hemiparesis  3 / 4 
Aphasia – disartria  5 
Mean lesion length (mm) 18 
Mean severity of stenosis (%) 84 
Bilateral carotid disease > 70% 5 
Contralateral carotid occlusion 2 
 
TABLE 3 
Procedural characteristics and 
angiographic results 
Characteristics  No. 
Embolic protection device  
(Boston/Abbott) 
6 / 14 
Stent (Boston/Abbott) 8 / 19 
Predilatation 8 
Postdilatation  17 
Residual stenosis (Mean + SD) 14 +6 
Results  
The demographic data of the study 
group shows an average age of 61 years 
(range from 48 to 72) and gender 
distribution of 18 men and 9 women. In 
terms of clinical aspects 12 patients were 
classified as high risk patients (6 suffered 
from significant contralateral carotid artery 
disease, 3 had old myocardial infarction 
with coronary stenting and 2 had multi-
vessel atherosclerosis.  One asymptomatic 
patient, who referred to us for carotid 
stenting treatment, required an open heart 
surgery in the following 30 days and one 
was known with left ventricular 
dysfunction with ejection deficit fraction 
under 40% (Table 1, 2). 
Good postdilatation results were 
obtained with residual stenosis less than 
20% in al cases (the mean residual stenosis 
was 14%). No subintimal dissection, arterial 
disruption or contrast extravasations were 
noted. Neurological examinations at two 
days and 2 months posinterventionl show 
no major modification comparative with 
the admission neurological status. Mild 
headache, lightheadness, dizziness or minor 
discomfort at the neck level, remitted 
completely in 24 hours were observed in 4 
patients. Three patients showed episodes of 
significant bradycardia after balloon 
dilatation. New stroke or deaths were not 
encountered at 6 months after the 
procedure, except one patient who 
experienced a temporary aphasia at 4 
month.         
Discussion  
Our experience concerning the carotid 
angioplasty with stent placement suggest 
that this technique it’s an efficient 
therapeutic alternative especially in those 
patients considered to be at higher risk for 
stroke. The short-term neurological and 
angiographic results of our patients series 
are well correlated with other largest series 
reports from the literature. Data from the 
most recent randomized trials reported a 
technical success rate of 98.4%, a minor 
stroke rate of 2.7%, a major stroke rate of 
1.49%, and a mortality rate of 0.88% (3).  
A rigorous comparison of the results 
provided by this study with those obtained 
from the published studies could not be 
done because of differences in patient’s 
number, neurological status at the 
admission and upper age limit.  
The European Carotid Stent Trial 
(ECST) had reported an overall sever 
stroke  and death rates of 7% in patients 








Asymptomatic Carotid Atherosclerosis 
Study (ACAS) had reported periprocedural 
stroke and death rates of 2.3% in lower-risk 
subset (3). Although, in our patients study 
there was no statistic difference between 
symptomatic group and the asymptomatic 
group, our results been more close to those 
obtained in ACAS. 
Some studies recommend the use of 
carotid protection device even if an intr-
stent balloon postdilatation is not necessary. 
Although, these studies mention a 
periprocedural increased risk due to not 
using a carotid protection device and during 
balloon postdilatation, we have not 
encountered such problems. We believe 
that the use of a carotid protection device 
for carotid stenting without balloon 
postdilatation is not absolutely necessary, 
and a reduction of balloon inflation time 
will minimize the disruptions of cerebral 
blood flow, especially in patients with 
contralateral carotid occlusion.  
The technical success rate of our 27 
consecutive carotid stenting procedures was 
100%. The mean residual stenosis 
immediately after stent implantation was 
14% indicating the feasibility of this 
procedure under optimal choice of 
materials and experienced specialist.  
Conclusions  
The carotid artery stenting was proven 
to be an optimal treatment for most of the 
patients with symptomatic carotid stenosis 
or asymptomatic severe carotid stenosis 
(>70%).  We need for a long-time study 
including a greater number of patients in 
order to make a correct statistical analysis 
with other multicenter studies.  Finally, our 
study could be a guide for the other 
neurosurgeon colleagues who wants to 
implement this treatment technique in their 
departments. 
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